Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy

Administration of topical bevacizumab 4 mg/ml for two weeks following trabeculectomy with mitomycin-C did not significantly affect the IOP trend, but significantly decreased the cystic bleb formation in short-term follow-up.